Hansa Biopharma AB (publ) logo

Hansa Biopharma AB (publ)

SSE:HNSA.ST

Overview | Financials
Company Name Hansa Biopharma AB (publ)
Symbol HNSA.ST
Currency SEK
Price 32.64
Market Cap 1,719,207,552
Dividend Yield 0%
52-week-range 20.14 - 58.1
Industry Biotechnology
Sector Healthcare
CEO Mr. Søren Tulstrup M.Sc
Website https://www.hansabiopharma.com

An error occurred while fetching data.

About Hansa Biopharma AB (publ)

Hansa Biopharma AB (publ), a biopharmaceutical company, develops immunomodulatory treatments for enabling transplants and rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy, and cancer using its proprietary enzyme technology platform. The company's lead drug candidate is Imlifidase, an antibody cleaving enzyme therapy that is in phase 3 clinical trial for

Related Stocks

BioInvent International AB (publ) logo

BioInvent International AB (publ)

BINV.ST

16.58 SEK

Q-linea AB (publ) logo

Q-linea AB (publ)

QLINEA.ST

2.49 SEK

Humana AB (publ) logo

Humana AB (publ)

HUM.ST

27 SEK

Elos Medtech AB (publ) logo

Elos Medtech AB (publ)

ELOS-B.ST

203 SEK

RaySearch Laboratories AB (publ) logo

RaySearch Laboratories AB (publ)

RAY-B.ST

92.2 SEK

Vicore Pharma Holding AB (publ) logo

Vicore Pharma Holding AB (publ)

VICO.ST

14.38 SEK

Intervacc AB (publ) logo

Intervacc AB (publ)

IVACC.ST

3.735 SEK

IRLAB Therapeutics AB (publ) logo

IRLAB Therapeutics AB (publ)

IRLAB-A.ST

14.45 SEK

Doxa AB (publ) logo

Doxa AB (publ)

DOXA.ST

3.2 SEK

Financials

Numbers are in millions USD

Numbers are in millions USD